key: cord-0884524-xir0u7k8 authors: Nicholson, Erin G.; Avadhanula, Vasanthi; Fragoso, Sonia; Stroh, Rachel; Ye, Xunyan; Bond, Nanette; Santarcangelo, Patricia; Stroh, John; Piedra, Pedro A title: SARS‐CoV‐2 re‐infection versus prolonged shedding: A case series date: 2021-06-04 journal: Influenza Other Respir Viruses DOI: 10.1111/irv.12879 sha: 04459239a4a6180e0940176d62ff55ed6f954d66 doc_id: 884524 cord_uid: xir0u7k8 Since the start of the SARS‐CoV‐2 pandemic, it has been difficult to differentiate between SARS‐CoV‐2 re‐infection and prolonged RNA shedding. In this report, we identified patients with positive RT‐PCR results for SARS‐CoV‐2 ≥70 days apart. Clinical and laboratory data were collected and criteria were applied to discern whether the presentation was consistent with SARS‐CoV‐2 re‐infection or prolonged viral RNA shedding. Eleven individuals met the initial testing criteria, of which, seven met at least one criteria for re‐infection and four were consistent with prolonged RNA shedding. These data demonstrate the need for criteria to differentiate SARS‐CoV‐2 re‐infection from prolonged RNA shedding. Since the beginning of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic, the potential for re-infection with the SARS-CoV-2 virus has been a concern. Endemic coronaviruses are known to re-infect individuals in the same year, so it is plausible that natural infection with SARS-CoV-2 would similarly provide short-lived immunity. However, due to prolonged viral RNA shedding of the SARS-CoV-2 virus, it has been difficult to differentiate prolonged shedding from true re-infection. 1 This has changed in recent months when several reports emerged of individuals reinfected with genetically different lineages of SARS-CoV-2. 2,3 These reports represent confirmation that, while uncommon, re-infection in the span of several months with SARS-CoV-2 can occur. Currently, the Center for Disease Control (CDC) does not recommend testing individuals for re-infection less than 90 days since symptom onset. 4, 5 However, detailed SARS-CoV-2 real-time reverse transcriptase polymerase chain reaction (RT-PCR) kinetics data appear to describe a cessation of viral RNA shedding after 70 days in the majority of individuals (though exceptions have been described). [6] [7] [8] In this brief report, we describe the clinical characteristics and laboratory results of individuals with multiple positive SARS-CoV-2 RT-PCR results that extend beyond 70 days. The data described were obtained from two sources. The first is from our diagnostic operation for SARS-CoV-2 testing in a Clinical Laboratory Improvement Amendments (CLIA) Certified Respiratory Virus Diagnostic Laboratory (ID#: 45D0919666) that began on March 18, 2020. 9 The second source came from RT-PCR positive SARS-CoV-2 patients who enrolled in our ongoing study to evaluate antibody response kinetics after their primary infection. We included patients with 2 or more positive RT-PCR tests for SARS-CoV-2 that were at least 70 days apart in order to fully capture a spectrum of patients with prolonged viral RNA shedding vs re-infection. Based on proposed re-infection criteria in the literature, we defined three separate criteria to classify a patient as having a reinfection with SARS-CoV-2. The criteria are as follows: (1) a positive SARS-CoV-2 RT-PCR test at least 90 days after individuals first became symptomatic with SARS-CoV-2 and subsequently become asymptomatic, 4 (2) at least 2 negative RT-PCR tests for SARS-CoV-2 between two positive tests, 10,11 and (3) at least one negative RT-PCR test for SARS-CoV-2 between two positive tests more than 28 days apart. 12 For our analysis, only one criterion was needed to be considered a probable re-infection. We collected demographic, laboratory, and clinical data from retrospective chart review and performed phone interviews using a structured questionnaire. The protocol was approved by the institutional review board at Baylor College of Medicine. Mid-turbinate swabs were tested for SARS-CoV-2 using CDC's EUA The humoral IgG anti-spike enzyme-linked immunosorbent assays (ELISA) were performed as part of our IRB-approved research study. The SARS-CoV-2 full spike (S) protein used in the ELISA was kindly provided by Gale Smith (Novavax). 13 Of these 11 individuals, 6 were female with an average age of 49 years ( We used three criteria to assess the likelihood of a SARS-CoV-2 reinfection that occurred greater than 70 days after primary infection (described above). We found that 7 of the 11 individuals met at least one criterion for probable re-infection and all 7 of these individuals met Criteria 1 (see Figure 1 and Table 1 Six of the 11 individuals had IgG serology testing for SARS-CoV-2 (Table 1 ). Only two individuals (patients 1 and 3) had a paired sample whose sera was collected before and after their probable re-infection. Neither of these individuals mounted an increase in IgG anti-S antibody levels after their probable re-infection (Table 1) . This was a single site cohort study that reported on approximately seven months of RT-PCR testing for SARS-CoV-2. The low viral RNA content in the samples collected from probable re-infection cases precluded our ability to confirm the re-infection event using sequencing. The occurrence of probable re-infection with SARS-CoV-2 in our population seemed to be an uncommon occurrence that was associated with mild symptomatology at the time of their primary infection. Our data does support the CDC's recommendation that testing for SARS-CoV-2 re-infection is not needed prior to 90 days after symptoms arise. The peer review history for this article is available at https://publo ns.com/publo n/10.1111/irv.12879. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. Erin G. Nicholson https://orcid.org/0000-0001-9053-9429 An unusual COVID-19 case with over four months of viral shedding in the presence of low neutralizing antibodies: a case report COVID-19) re-infection by a phylogenetically distinct severe acute respiratory syndrome coronavirus 2 strain confirmed by whole genome sequencing. Clin Infect Dis. 2020. Epub ahead of print Evidence of SARS-CoV-2 re-infection with a different genotype Div Viral Dis Duration of isolation and precautions for adults with COVID-19 | CDC Kinetics of SARS-CoV-2 positivity of infected and recovered patients from a single center Respiratory syncytial virus vaccination during pregnancy and effects in infants Persistent SARS-COV-2 RNA positivity in a patient for 92 days after disease onset: a case report Viral load of SARS-CoV-2 in adults during the first and second wave of COVID-19 pandemic in Houston, TX: the potential of the super-spreader Positive RT-PCR test results after consecutively negative results in patients with COVID-19 Re-infection by COVID-19: a real threat for the future management of pandemia? Setting the criteria for SARS-CoV-2 reinfection -six possible cases Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine Serologic responses in healthy adult with SARS-CoV-2 reinfection Adaptive immune responses to SARS-CoV-2 infection in severe versus mild individuals SARS-CoV-2 re-infection versus prolonged shedding: A case series